Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

 
• By Joseph Haas

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Kidney
BMS and Exelixis hope they'll have the best combo data for first-line RCC

More from Clinical Trials

More from R&D